top of page
Approved
Product
Target
Indication
Preclinical
Phase 1a
Phase 1b
Phase 2
Phase 3
NDA/BLA
Oncology-ADC
PD-L1
Solid Tumors
EGFR
RET
Solid Tumors
STING
Solid Tumors
Non-Oncology
Solid Tumors
Asthma
TSLP
FXI/FXIa
Thromboembolic disorders
Oncology- Other Modalities
bottom of page